Trial Profile
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF 6297 After Single and Repeated Ascending Doses in Healthy Male Subjects Followed by a Repeated Dose in COPD Patients and a 2-way, Crossover, Double-blind, Placebo-controlled, Repeated Dose Part to Investigate the Anti-inflammatory Effect of CHF 6297 After Lipopolysaccaride (LPS) Challenge in Healthy Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs CHF 6297 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man
- Sponsors Chiesi Farmaceutici
- 02 May 2019 Status changed from recruiting to discontinued.
- 10 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 May 2019.
- 10 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 May 2019.